What is the Life Expectancy with Scleroderma?

If you are reading this after a recent diagnosis, take a deep breath. While a diagnosis of scleroderma is serious, modern medicine offers a lot of hope for a long, fulfilling life. How long you can expect to live depends entirely on the specific type of scleroderma you have. For people with localized scleroderma, the condition is generally limited to the skin and does not reduce life expectancy ^[1][2]. For those with systemic sclerosis, the disease can affect internal organs, which makes it more complex. However, thanks to major medical advances over the last few decades, survival rates have dramatically improved, and many people live long lives by managing the disease as a chronic condition ^[3][4].

Beware of Outdated Statistics Online

When patients search for “scleroderma survival rates,” they often encounter terrifying statistics from decades ago. It is important to know that these numbers do not reflect modern medicine. Historically, complications like scleroderma renal crisis (SRC)—a sudden, severe increase in blood pressure causing kidney failure—were almost always fatal within a year ^[5][6]. Today, the use of ACE inhibitors (a common class of blood pressure medications) has revolutionized the treatment of SRC, making it highly manageable and drastically reducing mortality ^[5][6][7].

You may wonder why exact modern survival percentages aren’t listed everywhere. This is because providing a single “scleroderma survival rate” is misleading. The spectrum of the disease is incredibly broad. Survival is driven entirely by which specific subtype you have and whether major internal organs are involved ^[8][9].

Understanding Prognosis by Type

Localized Scleroderma

Conditions like morphea and linear scleroderma fall under this category. They cause inflammation and thickening of the skin and underlying tissues but do not affect internal organs. Because it does not involve the heart, lungs, or kidneys, localized scleroderma does not impact your lifespan compared to the general population ^[1][2].

Systemic Sclerosis

Systemic sclerosis can involve internal organs and is divided into two main subtypes:

• Limited cutaneous systemic sclerosis (lcSSc): Often progresses more slowly. Organ involvement is less frequent and takes longer to develop ^[10][11].
• Diffuse cutaneous systemic sclerosis (dcSSc): Tends to progress more rapidly. Patients with this type have a higher risk of early major organ involvement, requiring closer monitoring and aggressive early treatment ^[10][11].

How Modern Treatments Have Changed Survival

Today, life expectancy in systemic sclerosis is primarily determined by whether the lungs, heart, or kidneys are affected ^[12][13]. Fortunately, modern medicine has completely changed the landscape for managing these complications:

• Interstitial Lung Disease (ILD): ILD causes scarring (fibrosis) in the lungs. In the past, this was very difficult to treat. Now, doctors use immunosuppressants like mycophenolate mofetil (MMF) and newer antifibrotic medications like nintedanib to stabilize lung function and slow disease progression ^[14][15].
• Pulmonary Arterial Hypertension (PAH): PAH is high blood pressure in the arteries of the lungs. Routine screening means this condition is caught much earlier today. Early use of combination therapies to open the blood vessels has significantly improved long-term survival for SSc-PAH patients ^[16][17].
• Scleroderma Renal Crisis (SRC): Early detection and aggressive blood pressure control with ACE inhibitors are now standard protocol. While SRC remains a serious complication, these medications prevent it from being universally fatal, with modern 5-year survival rates improving to 60-70% ^[7][18].
• Gastrointestinal (GI) Involvement: While lung and heart complications are the primary drivers of mortality, severe GI issues like dysmotility (food moving too slowly) and malabsorption can significantly impact long-term prognosis and daily quality of life ^[8].

Living with Scleroderma Today

Because systemic sclerosis is highly variable, your prognosis is unique to your symptoms and how quickly your body responds to treatment. Age at diagnosis also plays a role, with older individuals (over 60) generally facing higher risks ^[19]. While this page focuses heavily on survival, it is important to recognize that the daily grind of scleroderma—dealing with severe fatigue, Raynaud’s phenomenon, and joint pain—significantly impacts your quality of life even when it doesn’t impact your lifespan.

The key to a good prognosis is proactive monitoring. Catching organ involvement before it causes symptoms allows for early, aggressive treatment. You should expect regular screenings from your rheumatologist, including:

• Pulmonary Function Tests (PFTs): Breathing tests to check for early lung scarring (ILD).
• Echocardiograms: Ultrasounds of the heart to screen for pulmonary hypertension (PAH).
• Routine Blood Pressure Checks: To monitor for early signs of kidney involvement (SRC).

By working closely with a rheumatologist who specializes in scleroderma and reporting new symptoms immediately—such as sudden high blood pressure, new shortness of breath, or a severe headache—the disease can often be managed as a chronic, long-term condition.